Preladenant | SCH-420814 | Adenosine Receptor Antagonist

首页 / 抑制剂/激动剂 / G蛋白偶联受体/G蛋白 / 腺苷受体 / Preladenant

Preladenant {[allProObj[0].p_purity_real_show]}

货号：A120930 同义名： SCH-420814;MK-3814

Preladenant is a highly selective and competitive A2A receptor antagonist with Ki value of 1.1nM, used in trials studying the treatment of brain diseases, such as parkinson disease, movement disorders, antipsychotic agents and parkinsonian disorders.

Preladenant 化学结构
CAS号：377727-87-2

Preladenant 3D分子结构
CAS号：377727-87-2

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Preladenant 纯度/质量文件产品仅供科研

货号：A120930 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]; • JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]; • BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]; • J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]; • PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]; 更多 >

腺苷受体亚型比较

产品名称	Adenosine Receptor ↓ ↑	纯度
ZM241385	✔	99%+
Istradefylline	+++ Adenosine A2A receptor, Ki: 2.2 nM	98%
Reversine	+ human A3 adenosine receptor, Ki: 0.66 μM	98%
SCH58261	++++ rat A2a, Ki: 2.3 nM bovine A2a, Ki: 2.0 nM	99%+
A2A receptor antagonist 1	++ A2AR, Ki: 4 nM A1R, Ki: 264 nM	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Preladenant 生物活性

描述	Preladenant is a potent competitive antagonist of the human A2A receptor (Ki=1.1 nM) and has > 1000-fold selectivity over all other adenosine receptors.

Preladenant 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT00406029	Parkinson Disease ... 展开 >> Movement Disorders Central Nervous System Diseases Neurodegenerative Diseases Brain Diseases 收起 <<	Phase 2	Completed	-	-
NCT01155466	Parkinson Disease	Phase 3	Completed	-	-
NCT01215227	Parkinson Disease ... 展开 >> Idiopathic Parkinson Disease 收起 <<	Phase 3	Terminated	-	-

Preladenant 参考文献

[1]Hodgson RA, Bedard PJ, et al. Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders. Exp Neurol. 2010 Oct;225(2):384-90.

[2]Hodgson RA, Bertorelli R, et al. Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl] -1-piperazinyl] ethyl] -2-(2-furanyl)-7H-pyrazolo[4,3-e ] [1,2,4] triazolo[1,5-c] pyrimidin-5-amine] in rodent models of movement disorders and depression. J Pharmacol Exp Ther. 2009 Jul;330(1):294-303.

Preladenant 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

1.99mL

0.40mL

0.20mL

9.93mL

1.99mL

0.99mL

19.86mL

3.97mL

1.99mL

Preladenant 技术信息

CAS号	377727-87-2
分子式	C₂₅H₂₉N₉O₃
分子量	503.556

别名	SCH-420814;MK-3814;Privadenant
运输	蓝冰

存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Sealed in dry,Store in freezer, under -20°C

溶解度

DMSO: 4 mg/mL(7.94 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

摩尔计算器

计算溶液所需的质量，体积或浓度。 Ambeed 摩尔浓度计算器基于以下方程式：

浓度 (mol/L) × 体积 (L) × 分子量 (g/mol)=质量 (g)

浓度

体积

分子量

质量

*在制备母液时，请始终参考产品标签或 MSDS / COA（在产品页面可下载）上所显示的对应批次产品的分子量。

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT00406029	Parkinson Disease ... 展开 >> Movement Disorders Central Nervous System Diseases Neurodegenerative Diseases Brain Diseases 收起 <<	Phase 2	Completed	-	-
NCT01155466	Parkinson Disease	Phase 3	Completed	-	-
NCT01215227	Parkinson Disease ... 展开 >> Idiopathic Parkinson Disease 收起 <<	Phase 3	Terminated	-	-
NCT01155479	Parkinson Disease	Phase 3	Terminated(Termininated for bu... 展开 >>siness reasons) 收起 <<	-	-
NCT00845000	Parkinson Disease	Phase 1	Completed	-	-
NCT01155466	-		Completed	-	-
NCT00845000	-		Completed	-	-
NCT00406029	-		Completed	-	-
NCT00693472	Akathisia, Drug-Induced ... 展开 >> Antipsychotic Agents Movement Disorders 收起 <<	Phase 2	Terminated	-	-
NCT00693472	-		Terminated	-	-
NCT01215227	-		Terminated	-	-
NCT01155479	-		Terminated(Termininated for bu... 展开 >>siness reasons) 收起 <<	-	-
NCT00537017	-		Completed	-	-
NCT00686699	Akathisia, Drug-Induced ... 展开 >> Dyskinesia, Drug-Induced Parkinsonian Disorders 收起 <<	Phase 2	Terminated(The study was termi... 展开 >>nated after 9 participants completed due to lack of enrollment for 6 months.) 收起 <<	-	-
NCT00686699	-		Terminated(The study was termi... 展开 >>nated after 9 participants completed due to lack of enrollment for 6 months.) 收起 <<	-	-
NCT01294800	Parkinson's Disease	Phase 2	Completed	-	-
NCT01294800	-		Completed	-	-
NCT01227265	Parkinson Disease ... 展开 >> Idiopathic Parkinson Disease Idiopathic Parkinson's Disease 收起 <<	Phase 3	Completed	-	-
NCT03099161	Neoplasm	Phase 1	Terminated("The data did not s... 展开 >>upport study endpoints") 收起 <<	-	United States, Michigan ... 展开 >> START Midwest ( Site 0001) Grand Rapids, Michigan, United States, 49546 Canada, Ontario Princess Margaret Hospital ( Site 0010) Toronto, Ontario, Canada, H9H 4M7 Canada, Quebec Jewish General Hospital ( Site 0011) Montreal, Quebec, Canada, H9H 4M7 Israel Rambam Health Care Campus ( Site 0020) Haifa, Israel Tel Aviv Sourasky Medical Center ( Site 0021) Tel Aviv, Israel 收起 <<
NCT01323855	Parkinson Disease	Phase 1	Completed	-	-
NCT01323855	-		Completed	-	-
NCT00537017	Parkinson Disease ... 展开 >> Neurodegenerative Diseases Central Nervous System Diseases Movement Disorders Brain Diseases 收起 <<	Phase 2	Completed	-	-
NCT01465412	Chronic Hepatic Impairment	Phase 1	Completed	-	-
NCT01227265	-		Completed	-	-
NCT01465412	-		Completed	-	-

Preladenant {[allProObj[0].p_purity_real_show]}

Preladenant 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Preladenant 质控信息

Preladenant 生物活性

Preladenant 临床研究

Preladenant 参考文献

Preladenant 实验方案

Preladenant 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Preladenant {[allProObj[0].p_purity_real_show]}

Preladenant 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Preladenant 质控信息

Preladenant 生物活性

Preladenant 临床研究

Preladenant 参考文献

Preladenant 实验方案

Preladenant 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Preladenant 纯度/质量文件产品仅供科研